ICON plc reports developments for a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology companies. Its news commonly covers operating and financial results, clinical trial management activity, net business wins, revenue guidance, and service areas such as patient recruitment, data analytics, laboratory services and regulatory consulting.
Company updates also address partnerships that connect clinical trial technology with research-site systems, expansion of the Accellacare Site Network in therapeutic areas including oncology, and governance or accounting-control matters tied to revenue recognition and financial reporting.
ICON (NASDAQ: ICLR) will host its 2024 Investor Day in New York City, featuring presentations from its executive team outlining strategic initiatives and financial outlook. ICON updated its 2024 guidance, expecting adjusted earnings per share (EPS) to range between $14.75 and $15.25, representing a 15.3% to 19.2% increase over 2023. Full-year revenue is projected to be between $8,480 million and $8,720 million, marking a 4.4% to 7.4% year-over-year increase. The company has also refined its debt structure, including a $2 billion bond offering and Term Loan B repricing, which is expected to result in a net interest expense of $200-$210 million in 2024.
ICON, a leading healthcare intelligence and clinical research organization, has announced an Investor Day event on May 30, 2024, in New York City. Starting at 10 AM ET, the event will feature presentations from ICON's executive team and a question-and-answer session, concluding around 1 PM ET. A live webcast of the event will be available on ICON's Investor section of their website. Any updates or changes will also be posted there.
ICON plc, a healthcare intelligence and clinical research organization, released its ICON Cares 2023 Report. The report highlights the company's achievements in ESG, diversity, inclusion, and sustainability goals. ICON received recognition for its efforts, including a gold medal status from EcoVadis and being named one of Europe's Climate Leaders in 2024. The company focused on increasing access to clinical trials, promoting workplace diversity, conducting business sustainably, and supporting communities.
ICON plc announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of three tranches with varying maturity dates. The Notes will be issued by ICON's subsidiary and guaranteed by ICON and its subsidiaries. The offering is expected to close on May 8, 2024, with proceeds used to repay existing debt and cover related expenses.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.